The incretin system in the management of type 2 diabetes mellitus.
Diabetes Research Group, Institute of Life Sciences, Swansea University. J.W.Stephens@Swansea.ac.uk
Jeffrey W
JW
Stephens
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000494:pharmacology; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000037:antagonists & inhibitors / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006801:Humans; D054795:Incretins / Q000494:pharmacology*; D000069450:Liraglutide
D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D054795:Incretins; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases